145 related articles for article (PubMed ID: 27140406)
1. TG4010: a vaccine with a therapeutic role in cancer.
Arriola E; Ottensmeier C
Immunotherapy; 2016 May; 8(5):511-9. PubMed ID: 27140406
[TBL] [Abstract][Full Text] [Related]
2. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Quoix E; Lena H; Losonczy G; Forget F; Chouaid C; Papai Z; Gervais R; Ottensmeier C; Szczesna A; Kazarnowicz A; Beck JT; Westeel V; Felip E; Debieuvre D; Madroszyk A; Adam J; Lacoste G; Tavernaro A; Bastien B; Halluard C; Palanché T; Limacher JM
Lancet Oncol; 2016 Feb; 17(2):212-223. PubMed ID: 26727163
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.
Ramlau R; Quoix E; Rolski J; Pless M; Lena H; Lévy E; Krzakowski M; Hess D; Tartour E; Chenard MP; Limacher JM; Bizouarne N; Acres B; Halluard C; Velu T
J Thorac Oncol; 2008 Jul; 3(7):735-44. PubMed ID: 18594319
[TBL] [Abstract][Full Text] [Related]
4. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
Acres B
J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
[TBL] [Abstract][Full Text] [Related]
5. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
6. Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC.
Tosch C; Bastien B; Barraud L; Grellier B; Nourtier V; Gantzer M; Limacher JM; Quemeneur E; Bendjama K; Préville X
J Immunother Cancer; 2017 Sep; 5(1):70. PubMed ID: 28923084
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.
Quoix E; Ramlau R; Westeel V; Papai Z; Madroszyk A; Riviere A; Koralewski P; Breton JL; Stoelben E; Braun D; Debieuvre D; Lena H; Buyse M; Chenard MP; Acres B; Lacoste G; Bastien B; Tavernaro A; Bizouarne N; Bonnefoy JY; Limacher JM
Lancet Oncol; 2011 Nov; 12(12):1125-33. PubMed ID: 22019520
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.
Hillman GG; Reich LA; Rothstein SE; Abernathy LM; Fountain MD; Hankerd K; Yunker CK; Rakowski JT; Quemeneur E; Slos P
J Immunother Cancer; 2017; 5():4. PubMed ID: 28116088
[TBL] [Abstract][Full Text] [Related]
9. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model.
Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W
Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167
[TBL] [Abstract][Full Text] [Related]
10. Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors.
Schaedler E; Remy-Ziller C; Hortelano J; Kehrer N; Claudepierre MC; Gatard T; Jakobs C; Préville X; Carpentier AF; Rittner K
Vaccine; 2017 Jan; 35(4):577-585. PubMed ID: 28012777
[TBL] [Abstract][Full Text] [Related]
11. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
12. Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats.
Zhang S; Zhang H; Shi H; Yu X; Kong W; Li W
Hum Immunol; 2008; 69(4-5):250-8. PubMed ID: 18486759
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.
Oudard S; Rixe O; Beuselinck B; Linassier C; Banu E; Machiels JP; Baudard M; Ringeisen F; Velu T; Lefrere-Belda MA; Limacher JM; Fridman WH; Azizi M; Acres B; Tartour E
Cancer Immunol Immunother; 2011 Feb; 60(2):261-71. PubMed ID: 21069322
[TBL] [Abstract][Full Text] [Related]
14. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
Rochlitz C; Figlin R; Squiban P; Salzberg M; Pless M; Herrmann R; Tartour E; Zhao Y; Bizouarne N; Baudin M; Acres B
J Gene Med; 2003 Aug; 5(8):690-9. PubMed ID: 12898638
[TBL] [Abstract][Full Text] [Related]
15. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.
Ryan SO; Turner MS; Gariépy J; Finn OJ
Cancer Res; 2010 Jul; 70(14):5788-96. PubMed ID: 20587526
[TBL] [Abstract][Full Text] [Related]
16. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
17. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
[TBL] [Abstract][Full Text] [Related]
18. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
19. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
Soares MM; Mehta V; Finn OJ
J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of agonist epitopes of the MUC1-C oncoprotein.
Jochems C; Tucker JA; Vergati M; Boyerinas B; Gulley JL; Schlom J; Tsang KY
Cancer Immunol Immunother; 2014 Feb; 63(2):161-74. PubMed ID: 24233342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
